title: Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis.
abstract: OBJECTIVE
  To evaluate the efficacy of filtration leucocytapheresis (LCP) for rheumatoid arthritis (RA).
  
  
  METHODS
  LCP was carried out three times, with 1 week separating each session, in 25 drug-resistant RA patients.
  
  
  RESULTS
  During each session, 96, 98, 61, 84 and 8% of the granulocytes, monocytes, lymphocytes, platelets and erythrocytes, respectively, that entered the LCP filter were removed. The number of granulocytes, monocytes and lymphocytes in the peripheral blood significantly decreased during each session of LCP. However, there was no significant decrease in the number of circulating blood cells during the study period. On average, 110 x 10(8) granulocytes, 5.23 x 10(8) monocytes, and 20.5 x 10(8) lymphocytes were removed during LCP therapy. Assessment of RA before and after LCP showed a substantial and rapid improvement in the tender joints counts, swollen joint counts, and patient's and physician's assessments. No adverse reactions or complications were noted. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels decreased following LCP, although the change in the latter parameter was statistically insignificant. The concentrations of serum albumin, gamma-globulin, IgG, IgM, CH50 and rheumatoid factor titres did not change during or after LCP. Careful analysis indicated that 16 of 25 patients with RA showed > or =20% improvement following LCP therapy.
  
  
  CONCLUSIONS
  Our results suggest that filtration LCP to remove leucocytes from the peripheral blood exerts an immunomodulatory effect in patients with RA.
authors.affiliation: Department of Internal Medicine, Sasebo Chuo Hospital, Sasebo, Asahi Medical Research and Development Laboratory, Oita, Asahi Medical Technical Department, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ueki
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kanamoto
authors.forename: T
authors.initials: T
authors.lastname: Kawazu
authors.forename: M
authors.initials: M
authors.lastname: Yano
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: S
authors.initials: S
authors.lastname: Miyake
authors.forename: Y
authors.initials: Y
authors.lastname: Tominaga
authors.forename: U
authors.initials: U
authors.lastname: Iwamoto
authors.forename: J
authors.initials: J
authors.lastname: Suemitsu
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Y
authors.initials: Y
authors.lastname: Sizume
authors.forename: Y
authors.initials: Y
authors.lastname: Takenaka
authors.forename: K
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D001172:Arthritis, Rheumatoid / Q000097:blood / Q000628:therapy*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D007596:Joints / Q000473:pathology; D007937:Leukapheresis / Q000295:instrumentation; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010146:Pain; D016896:Treatment Outcome
chemical_list: D002097:C-Reactive Protein